BCTX Stock Overview
Operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
BriaCell Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.14 |
| 52 Week High | CA$7.59 |
| 52 Week Low | CA$0.95 |
| Beta | 1.84 |
| 11 Month Change | -25.97% |
| 3 Month Change | -60.14% |
| 1 Year Change | -82.24% |
| 33 Year Change | -77.20% |
| 5 Year Change | -94.15% |
| Change since IPO | -97.01% |
Recent News & Updates
Recent updates
BriaCell stock rises on license deal for anti-cancer agent
Aug 04BriaCell partners with Waisman Biomanufacturing to make & supply prostate cancer therapy
Jul 05BriaCell, Harvard enter research agreement to identify targets for cancer treatments
Jun 29BriaCell Therapeutics receives proceed of $12.88M from warrant exercises
Jun 10BriaCell Therapeutics skyrockets 104% on robust overall survival benefit in advanced breast cancer patients
Jun 02Shareholder Returns
| BCTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.6% | -0.3% | 0.3% |
| 1Y | -82.2% | 11.0% | 22.5% |
Return vs Industry: BCTX underperformed the US Biotechs industry which returned 11% over the past year.
Return vs Market: BCTX underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| BCTX volatility | |
|---|---|
| BCTX Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BCTX's share price has been volatile over the past 3 months.
Volatility Over Time: BCTX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 16 | Bill Williams | briacell.com |
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.
BriaCell Therapeutics Corp. Fundamentals Summary
| BCTX fundamental statistics | |
|---|---|
| Market cap | US$18.84m |
| Earnings (TTM) | -US$6.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.4x
P/E RatioIs BCTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.00m |
| Earnings | -US$6.00m |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BCTX perform over the long term?
See historical performance and comparison